Transthyretin amyloidosis: the picture is getting clearer
- PMID: 35912914
- DOI: 10.1002/ejhf.2641
Transthyretin amyloidosis: the picture is getting clearer
Comment on
-
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis.Eur J Heart Fail. 2022 Sep;24(9):1677-1696. doi: 10.1002/ejhf.2589. Epub 2022 Aug 2. Eur J Heart Fail. 2022. PMID: 35730461
References
-
- Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641-54.
-
- Rubin J, Maurer MS. Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 2020;71:203-19.
-
- Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286-300.
-
- Muller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail. 2020;22:39-53.
-
- Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42:1554-68.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials